Latest News for CERO
Fifth patient treated with CER-1236 underwent stem cell transplant following lack of response to prior therapies; Company initiates third planned cohort in ongoing Phase 1 study in hematologic malignancies
Fifth patient treated with CER-1236 underwent stem cell transplant following lack of response to prior therapies; Company initiates third planned cohort in ongoing Phase 1 study in hematologic malignancies SOUTH SAN FRANCISCO, Calif, June 15, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc.
Company to initiate third planned cohort at higher dose level, including patients with myelodysplastic syndrome and myelofibrosis
Company to initiate third planned cohort at higher dose level, including patients with myelodysplastic syndrome and myelofibrosis SOUTH SAN FRANCISCO, Calif. , May 11, 2026 (GLOBE NEWSWIRE) -- CERo Therapeutics Holdings, Inc. (OTCQB: CERO) ("CERo" or the "Company"), an innovative cellular immunotherapy company advancing next-generation engineered T cell therapeutics that employ phagocytic mechanisms, announces that…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for CERO.
U.S. House Trading
No House trades found for CERO.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.